Clinical trial
Overcome Biochemical Aspirin Resistance Through Cilostazol Combination
NCT00446641 · Asan Medical Center, Other · Completed
Key facts
| NCT number | NCT00446641 |
|---|---|
| Title | Overcome Biochemical Aspirin Resistance Through Cilostazol Combination |
| Official title | Phase 4 Study of Additional Cilostazol for Overcoming Biochemical Aspirin Resistance in the Chronic Stroke Patients |
| Acronym | ARCC |
| Lead sponsor | Asan Medical Center, Other |
| Collaborators | Korea Otsuka Pharmaceutical Co., Ltd. Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Cerebral Infarction |
| Intervention type | Drug |
| Interventions | Cilostazol, placebo |
| Enrollment | 244 |
| Start date | Mar 1, 2007 |
| Primary completion | Jun 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Mar 13, 2007 |
| Last update posted | Jan 18, 2010 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: